Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis
Links shared publicly online about this topic.
- 536total visits
Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis
Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.
View full resource at news-medical.net
Tags: Arthritis, Rheumatoid Arthritis, Healthcare, Pharma
Most Recently Shared on February 2, 2011 at 8:52 am By:
Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis: Antares Pharma, Inc. today announ... http://bit.ly/ejKqHB
Antares Pharma Announces First Rheumatoid Arthritis Patient Dosed in VIBEX™ MTX Clinical Trial | Business Wire
businesswire.com — “Antares Pharma, Inc. (NYSE Amex: AIS) today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX produc” View full resource at businesswire.com
Most Recently Shared on February 1, 2011 at 2:46 pm By:
Antares Pharma Announces First Rheumatoid Arthritis Patient Dosed in VIBEXâ„¢ MTX Clinical Trial: EWING, N.J.--(BU... http://bit.ly/eDM5cT
Advertisement
